07:37 AM EDT, 05/13/2025 (MT Newswires) -- Satellos Bioscience ( MSCLF ) on Tuesday reported a wider first-quarter loss due to higher research and development, and general and administrative expenses.

The company, which is developing medicines to treat degenerative muscle diseases, said its net loss widened to $6.1 million, or $0.04 per share, from $5.1 million, or $0.05 per share, for the prior year period.

Satellos will share data from its Phase 1b study in adult Duchenne muscle disease (DMD) patients in the second quarter, said Chief Executive Frank Gleeson.

"As a company, we believe we are well positioned to advance our novel drug into a randomized, placebo-controlled Phase 2 POC [proof-of-concept] trial in pediatric DMD patients as our next major development step," Gleeson said. "This study will be designed to further assess the safety of SAT-3247 in a key pediatric population, while exploring its possible utility in restoring the body's ability to repair and regenerate damaged or lost muscle."